AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT00085969
- Locations
- 🇺🇸
Mercury Street Medical Group, Butte, Montana, United States
🇺🇸MedStar Research Institute, Washington, District of Columbia, United States
🇺🇸Metrolina Medical Research, Charlotte, North Carolina, United States
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 535
- Registration Number
- NCT00085891
- Locations
- 🇺🇸
Research Site, Kirkland, Washington, United States
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
- Conditions
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 530
- Registration Number
- NCT00083954
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
- Conditions
- Interventions
- First Posted Date
- 2004-05-11
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 551
- Registration Number
- NCT00082381
- Locations
- 🇺🇸
Internal Medicine Associates Department of Research, Fort Myers, Florida, United States
🇳🇱Diabetes Centrum Bilthoven, Bilthoven, Netherlands
🇳🇱Medisch Centrum, Westeinde, Netherlands
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
- Conditions
- Interventions
- First Posted Date
- 2004-05-10
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 505
- Registration Number
- NCT00082407
- Locations
- 🇵🇹
Hospital Pedro Hispano, Matosinhos, Portugal
🇭🇷Clinical Hospital Osijek, Osijek, Croatia
🇭🇷Klinica bolnica Dubrava, Zagreb, Croatia
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
- First Posted Date
- 2004-05-06
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 237
- Registration Number
- NCT00082277
- Locations
- 🇬🇧
Research Site, Luton, United Kingdom
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00006049
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00006048
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
- Conditions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2008-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT00081380
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
- Conditions
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00079833
- Locations
- 🇫🇷
Research Site, Saint Germain en Laye, France